The control of Chagas disease, a neglected tropical disease caused by Trypansoma cruzi that is more prevalent in low-income populations, is one of the targets of the UN 2030 Agenda for Sustainable Development. However, Chagas disease is still a major public health issue, affecting 5–7 million people worldwide, mostly in Latin America, but with an increasing number of cases in the USA and Europe due to human migration. Chronic Chagas cardiomyopathy (CCC) is present in 30–40% of patients with chronic Chagas disease, and it accounts for the majority of health-care costs and deaths in this population.

ATSN-101 is well tolerated 12 months after treatment, with no drug-related serious adverse events. Clinically significant improvements in retinal sensitivity were sustained in patients receiving the high dose.

Mental health professionals warn the law worsens stigma against people experiencing homelessness and risks violating their rights. Amy Booth reports.

The optimum number of units of blood and the associated number of blood donors required to meet a given population’s needs remain undetermined globally. Typically, a whole blood donation rate of ten donations per 1000 population, at a minimum, is necessary to meet a country’s blood needs. This rate is attributed to a WHO recommendation that 1% of a given country’s population should donate blood to ensure a blood supply that is sufficient to meet clinical needs. This often cited metric was first referenced in a 1971 WHO report, yet neither supporting data or references were provided, suggesting that it was flawed at its founding.